Search

Your search keyword '"Dash, Ranjeet P."' showing total 9 results
Start Over Author "Dash, Ranjeet P." Publication Year Range Last 3 years
9 results on '"Dash, Ranjeet P."'

1. Supplemental Figure 5 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Author

Lemberg, Kathryn M., primary, Zhao, Liang, primary, Wu, Ying, primary, Veeravalli, Vijayabhaskar, primary, Alt, Jesse, primary, Aguilar, Joanna Marie H., primary, Dash, Ranjeet P., primary, Lam, Jenny, primary, Tenora, Lukáš, primary, Rodriguez, Chabely, primary, Nedelcovych, Michael T., primary, Brayton, Cory, primary, Majer, Pavel, primary, Blakeley, Jaishri O., primary, Rais, Rana, primary, and Slusher, Barbara S., primary

Published
2023
Full Text
View/download PDF

2. Data from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Author

Lemberg, Kathryn M., primary, Zhao, Liang, primary, Wu, Ying, primary, Veeravalli, Vijayabhaskar, primary, Alt, Jesse, primary, Aguilar, Joanna Marie H., primary, Dash, Ranjeet P., primary, Lam, Jenny, primary, Tenora, Lukáš, primary, Rodriguez, Chabely, primary, Nedelcovych, Michael T., primary, Brayton, Cory, primary, Majer, Pavel, primary, Blakeley, Jaishri O., primary, Rais, Rana, primary, and Slusher, Barbara S., primary

Published
2023
Full Text
View/download PDF

3. Supplemental Figure 1 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Author

Lemberg, Kathryn M., primary, Zhao, Liang, primary, Wu, Ying, primary, Veeravalli, Vijayabhaskar, primary, Alt, Jesse, primary, Aguilar, Joanna Marie H., primary, Dash, Ranjeet P., primary, Lam, Jenny, primary, Tenora, Lukáš, primary, Rodriguez, Chabely, primary, Nedelcovych, Michael T., primary, Brayton, Cory, primary, Majer, Pavel, primary, Blakeley, Jaishri O., primary, Rais, Rana, primary, and Slusher, Barbara S., primary

Published
2023
Full Text
View/download PDF

4. Supplemental Figure 2 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Author

Lemberg, Kathryn M., primary, Zhao, Liang, primary, Wu, Ying, primary, Veeravalli, Vijayabhaskar, primary, Alt, Jesse, primary, Aguilar, Joanna Marie H., primary, Dash, Ranjeet P., primary, Lam, Jenny, primary, Tenora, Lukáš, primary, Rodriguez, Chabely, primary, Nedelcovych, Michael T., primary, Brayton, Cory, primary, Majer, Pavel, primary, Blakeley, Jaishri O., primary, Rais, Rana, primary, and Slusher, Barbara S., primary

Published
2023
Full Text
View/download PDF

5. Supplemental Figure 3 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Author

Lemberg, Kathryn M., primary, Zhao, Liang, primary, Wu, Ying, primary, Veeravalli, Vijayabhaskar, primary, Alt, Jesse, primary, Aguilar, Joanna Marie H., primary, Dash, Ranjeet P., primary, Lam, Jenny, primary, Tenora, Lukáš, primary, Rodriguez, Chabely, primary, Nedelcovych, Michael T., primary, Brayton, Cory, primary, Majer, Pavel, primary, Blakeley, Jaishri O., primary, Rais, Rana, primary, and Slusher, Barbara S., primary

Published
2023
Full Text
View/download PDF

6. Supplemental Figure 4 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Author

Lemberg, Kathryn M., primary, Zhao, Liang, primary, Wu, Ying, primary, Veeravalli, Vijayabhaskar, primary, Alt, Jesse, primary, Aguilar, Joanna Marie H., primary, Dash, Ranjeet P., primary, Lam, Jenny, primary, Tenora, Lukáš, primary, Rodriguez, Chabely, primary, Nedelcovych, Michael T., primary, Brayton, Cory, primary, Majer, Pavel, primary, Blakeley, Jaishri O., primary, Rais, Rana, primary, and Slusher, Barbara S., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Table 1 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Author

Lemberg, Kathryn M., primary, Zhao, Liang, primary, Wu, Ying, primary, Veeravalli, Vijayabhaskar, primary, Alt, Jesse, primary, Aguilar, Joanna Marie H., primary, Dash, Ranjeet P., primary, Lam, Jenny, primary, Tenora, Lukáš, primary, Rodriguez, Chabely, primary, Nedelcovych, Michael T., primary, Brayton, Cory, primary, Majer, Pavel, primary, Blakeley, Jaishri O., primary, Rais, Rana, primary, and Slusher, Barbara S., primary

Published
2023
Full Text
View/download PDF

8. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

Author

Rais, Rana, primary, Lemberg, Kathryn M., additional, Tenora, Lukáš, additional, Arwood, Matthew L., additional, Pal, Arindom, additional, Alt, Jesse, additional, Wu, Ying, additional, Lam, Jenny, additional, Aguilar, Joanna Marie H., additional, Zhao, Liang, additional, Peters, Diane E., additional, Tallon, Carolyn, additional, Pandey, Rajeev, additional, Thomas, Ajit G., additional, Dash, Ranjeet P., additional, Seiwert, Tanguy, additional, Majer, Pavel, additional, Leone, Robert D., additional, Powell, Jonathan D., additional, and Slusher, Barbara S., additional

Published
2022
Full Text
View/download PDF

9. Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs

Author

Nedelcovych, Michael, Dash, Ranjeet P., Tenora, Lukáš, Zimmermann, Sarah C., Gadiano, Alexandra J., Garrett, Caroline, Alt, Jesse, Hollinger, Kristen R., Pommier, Elie, Jančařík, Andrej, Rojas, Camilo, Thomas, Ajit G., Wu, Ying, Wozniak, Krystyna, Majer, Pavel, Slusher, Barbara S., and Rais, Rana

Abstract

2-(Phosphonomethyl)pentanedioic acid (2-PMPA) is a potent and selective inhibitor of glutamate carboxypeptidase-II (GCPII) with efficacy in multiple neurological and psychiatric disease models, but its clinical utility is hampered by low brain penetration due to the inclusion of multiple acidic functionalities. We recently reported an improvement in the brain-to-plasma ratio of 2-PMPA after intranasal (IN) dosing in both rodents and primates. Herein, we describe the synthesis of several 2-PMPA prodrugs with further improved brain delivery of 2-PMPA after IN administration by masking of the γ-carboxylate. When compared to IN 2-PMPA in rats at 1 h post dose, γ-(4-acetoxybenzyl)-2-PMPA (compound 1) resulted in significantly higher 2-PMPA delivery to both plasma (4.1-fold) and brain (11-fold). Subsequent time-dependent evaluation of 1also showed high brain as well as plasma 2-PMPA exposures with brain-to-plasma ratios of 2.2, 0.48, and 0.26 for olfactory bulb, cortex, and cerebellum, respectively, as well as an improved sciatic nerve to plasma ratio of 0.84. In contrast, IV administration of compound 1resulted in similar plasma exposure of 2-PMPA versus the IN route (AUCIV: 76 ± 9 h·nmol/mL versus AUCIN: 99 ± 24 h·nmol/mL); but significantly lower nerve and brain tissue exposures with tissue-to-plasma ratios of 0.21, 0.03, 0.04, and 0.04 in nerve, olfactory bulb, cortex, and cerebellum, respectively. In primates, IN administration of 1more than doubled 2-PMPA concentrations in the cerebrospinal fluid relative to previously reported levels following IN 2-PMPA. The results of these experiments provide a promising strategy for testing GCPII inhibition in neurological and psychiatric disorders.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results